Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 5519 results found since Jan 2013.

Correlation between Vitamin D, homocysteine and brain-derived neurotrophic factor levels in patients with ischemic stroke
CONCLUSIONS: Vitamin D supplementation was used as a therapeutic agent in patients with acute ischemic stroke that affects homocysteine and BDNF levels. In this study, it was demonstrated for the first time that there is a correlation between serum vitamin D levels and BDNF levels in patients who have experienced a stroke.PMID:36394751 | DOI:10.26355/eurrev_202211_30154
Source: European Review for Medical and Pharmacological Sciences - November 17, 2022 Category: Drugs & Pharmacology Authors: U F Yurekli Z Tunc Source Type: research

Endovascular treatment for ischaemic stroke patients with and without atrial fibrillation, and the effects of adjunctive pharmacotherapy: a narrative review
Expert Opin Pharmacother. 2022 Dec 21. doi: 10.1080/14656566.2022.2161362. Online ahead of print.ABSTRACTINTRODUCTION: Endovascular thrombectomy (EVT) is associated with good clinical outcomes in anterior circulation ischaemic stroke. The impact of EVT on clinical outcomes in patients with ischaemic stroke with and without atrial fibrillation, and the effect of adjunctive pharmacological therapies with EVT, remains unclear.AREAS COVERED: The goal of this narrative review aims to provide an overview of studies which have examined: 1) associations between EVT and outcomes for patients following ischaemic stroke, 2) associati...
Source: Expert Opinion on Pharmacotherapy - December 21, 2022 Category: Drugs & Pharmacology Authors: Muath Alobaida Gregory Y H Lip Deirdre A Lane Dimitrios Sagris Andrew Hill Stephanie L Harrison Source Type: research

Research hotspots and frotiers of stem cells in stroke: A bibliometric analysis from 2004 to 2022
Conclusion: Between 2004 and 2022, the terms “neurogenesis,” “angiogenesis,” “mesenchymal stem cells,” “extracellular vesicle,” “exosomes,” “inflammation,” and “oxidative stress” have emerged as the hot research areas for research on stem cells in stroke. Although stem cells exert a number of positive effects, the main mechanisms for mitigating the damage caused by stroke are still unknown. Clinical challenges may include complicating factors that can affect the efficacy of stem cell therapy, which are worth a deep exploration.
Source: Frontiers in Pharmacology - March 3, 2023 Category: Drugs & Pharmacology Source Type: research

A novel small-molecular CCR5 antagonist promotes neural repair after stroke
In this study we characterized the therapeutic potential of a novel CCR5 antagonist A14 in treating ischemic stroke mice. A14 was discovered in screening millions compounds in the Chemdiv library based on the molecular docking diagram of CCR5 and maraviroc. We found that A14 dose-dependently inhibited the CCR5 activity with an IC50 value of 4.29 μM. Pharmacodynamic studies showed that A14 treatment exerted protective effects against neuronal ischemic injury both in vitro and vivo. In a SH-SY5Y cell line overexpressing CCR5, A14 (0.1, 1 μM) significantly alleviated OGD/R-induced cell injury. We found that the expression o...
Source: Acta Pharmacologica Sinica - May 17, 2023 Category: Drugs & Pharmacology Authors: Qing-Lin Wu Li-Yuan Cui Wen-Yu Ma Sha-Sha Wang Zhao Zhang Zhong-Ping Feng Hong-Shuo Sun Shi-Feng Chu Wen-Bin He Nai-Hong Chen Source Type: research

The role of RhoA/ROCK pathway in the ischemic stroke-induced neuroinflammation
Biomed Pharmacother. 2023 Jul 10;165:115141. doi: 10.1016/j.biopha.2023.115141. Online ahead of print.ABSTRACTIt is widely known that ischemic stroke is the prominent cause of death and disability. To date, neuroinflammation following ischemic stroke represents a complex event, which is an essential process and affects the prognosis of both experimental stroke animals and stroke patients. Intense neuroinflammation occurring during the acute phase of stroke contributes to neuronal injury, BBB breakdown, and worse neurological outcomes. Inhibition of neuroinflammation may be a promising target in the development of new thera...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 12, 2023 Category: Drugs & Pharmacology Authors: Weizhuo Lu Zhiwu Chen Jiyue Wen Source Type: research

Regulators of phagocytosis as pharmacologic targets for stroke treatment
Stroke, including ischemic and hemorrhagic stroke, causes massive cell death in the brain, which is followed by secondary inflammatory injury initiated by disease-associated molecular patterns released from dead cells. Phagocytosis, a cellular process of engulfment and digestion of dead cells, promotes the resolution of inflammation and repair following stroke. However, professional or non-professional phagocytes also phagocytose stressed but viable cells in the brain or excessively phagocytose myelin sheaths or prune synapses, consequently exacerbating brain injury and impairing repair following stroke. Phagocytosis inclu...
Source: Frontiers in Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Source Type: research

The role of heat shock protein 70 in the protective effect of YC-1 on heat stroke rats.
Abstract Heat stroke is a life-threatening illness characterized by an elevated core body temperature. Despite adequate lowering of the body temperature and support treatment of multiple organ-system function, heat stroke is often fatal. 3-(5'-Hydoxymethyl-2'-furyl)-1-benzyl-indazol (YC-1) been identified as an activator of soluble guanylate cyclase. To evaluate whether YC-1 protects multiple organ dysfunctions and improves survival during heat stroke and its mechanism. Male Sprague-Dawley rats untreated or treated with either YC-1 or quercetin (heat shock protein (Hsp) 70 inhibitor) were exposures to heat as a mo...
Source: European Journal of Pharmacology - December 5, 2012 Category: Drugs & Pharmacology Authors: Lam KK, Cheng PY, Lee YM, Liu YP, Cheng Ding J, Liu WH, Yen MH Tags: Eur J Pharmacol Source Type: research

Therapeutics targeting Nogo-A hold promise for stroke restoration.
Abstract Neurorestorative therapies for stroke aim to reverse disability by reparative mechanisms (rather than to thrombolyse or to neuroprotect). A substantial and persuasive body of pre-clinical evidence has come from the evaluation of antibodies against Nogo-A (a myelin-associated inhibitor of plasticity) in rat models of stroke. Particularly impressive is the benefit of this therapy in models of permanent middle cerebral artery occlusion (MCAO) when given to elderly animals after a one week delay, in adult rats with co-morbidities, and in adult rats when treatment is delayed by up to 9 weeks after stroke (alth...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Kumar P, Moon LD Tags: CNS Neurol Disord Drug Targets Source Type: research

Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities.
Abstract Stroke is the second leading cause of death, after ischemic heart disease, and accounts for 9% of deaths worldwide. According to the World Health Organization [WHO], 15 million people suffer stroke worldwide each year. Of these, more than 6 million die and another 5 million are permanently disabled. Reactive oxygen species [ROS] have been implicated in brain injury after ischemic stroke. There is evidence that a rapid increase in the production of ROS immediately after acute ischemic stroke rapidly overwhelm antioxidant defences, causing further tissue damage. These ROS can damage cellular macromolecules ...
Source: CNS and Neurological Disorders Drug Targets - February 27, 2013 Category: Drugs & Pharmacology Authors: Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, Feuerhake W Tags: CNS Neurol Disord Drug Targets Source Type: research

Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US.
CONCLUSIONS: This review identified several areas of uncertainty regarding the economic benefit of anticoagulants. The generalizability of cost-effectiveness results of anticoagulant therapy in AF based on clinical trial data must be confirmed by comparative effectiveness research conducted in the real-world setting. PMID: 23606551 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: von Schéele B, Fernandez M, Hogue SL, Kwong WJ Tags: Ann Pharmacother Source Type: research

Enteric-Coated Aspirin Versus Other Antiplatelet Drugs in Acute Non-Cardioembolic Ischemic Stroke: Post-marketing Study in Japan.
CONCLUSION: It seems that these results showed the safety and efficacy of the enteric-coated aspirin in acute stroke care in Japanese patients. Incidence of hemorrhagic events was comparable between the enteric-coated aspirin group and the other antiplatelet drugs group. PMID: 24385407 [PubMed - as supplied by publisher]
Source: Advances in Therapy - January 3, 2014 Category: Drugs & Pharmacology Authors: Takahashi S, Mizuno O, Sakaguchi T, Yamada T, Inuyama L Tags: Adv Ther Source Type: research